November 6, 2026 – Cepheid announced that the U.S. Food and Drug Administration (FDA) has cleared Xpert Hemorrhagic Fever Panel, a multiplex PCR test designed for the qualitative detection and identification of RNA from viruses that cause several viral hemorrhagic fevers from a single sample.
Xpert Hemorrhagic Fever Panel delivers results in approximately 61 minutes on Cepheid’s GeneXpert Dx systems. Its closed-cartridge design minimizes the risk of cross-contamination between samples, and the sample processing step includes viral inactivation to support safe laboratory workflows.
Xpert Hemorrhagic Fever Panel detects and identifies nucleic acids of the following viruses: Ebola virus (including Zaire, Sudan, Taï Forest, and Bundibugyo, not differentiated), as well as Marburg virus, Lassa virus, and Crimean-Congo hemorrhagic fever (CCHF) virus.